Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

Conclusions A combination of new and standard biomarkers consisting of CLU, ANG, C1Q, albumin, ß2M, paraprotein and K/L ratio may have potential as a novel panel of biomarkers to predict MM response to treatment containing bortezomib. General Significance Use of this biomarker panel could facilitate a more personalized therapy approach and to minimize unnecessary side effects from ineffective drugs.
Source: BBA Clinical - Category: Biochemistry Source Type: research